TITLE

EXPERIENCE WITH THE USE OF HUMAN FIBRINOLYSIN

AUTHOR(S)
Villavicencio, J. Leonel; Warren, Richard
PUB. DATE
August 1959
SOURCE
Angiology;Aug1959 Part 2, Vol. 10 Issue 4, p263
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
1. Experiences with the clinical and experimental administration of plasmin are reported. 2. Of the methods for the assay of plasma fibrinolytic activity which were tested (fibrin plate, euglobulin on fibrin clot, euglobulin on benzoyl arginine methyl ester (BAME), plasma on BAME, and whole blood spontaneous clot lysis) the two most practical seemed to be the action of the euglobulin fraction on a fibrin clot and the whole blood spontaneous clot lysis. 3. Thirty-one plasmin infusions in 22 patients gave evidence of marked clinical improvement in only one patient and a febrile reaction rate of 42 per cent. In 2 patients in whom clots were created experimentally at operation partial clot lysis was procured by the local injection of 50,000 and 100,000 units of plasmin intraarterially. 4. Experimental creation of intraarterial clots in dogs provided us with a preparation in which to test the action of plasmin in vivo. In all 6 dogs clot lysis was effected by its intraarterial injection of the plasmin just �upstream� from the clot. 5. Since experimental clot lysis in vivo is a reality, it remains only for the preparations of plasmin to be purified before therapeutic, clinical clot lysis becomes a fact.
ACCESSION #
16388365

 

Related Articles

  • Investigation of Kinetic Parameters In Vitro of Serine Proteinases Included in the Blood Coagulation Cascade. Danalev, Dantcho Lyubenov; Yotova, Lyubov Konstanitova; Vezenkov, Lyubomir Todorov // Protein & Peptide Letters;Jun2006, Vol. 13 Issue 6, p535 

    During the last years the cases and death due to hemostatic violations exceed that of tumors. Enormous efforts have devoted to the prevention and treatment of some diseases such as arterial thrombosis. Antistasin, a 15 kDa anticoagulant protein isolated from salivary glands of the Mexican leech...

  • Plexins.  // Encyclopedic Reference of Molecular Pharmacology;2004, p747 

    A definition of the term "plasmin" is presented. It refers to the serine protease that is responsible for degradation of fibrin during activitation of the fibrinolytic system. It cleaves fibrin into soluble fibrin degradation products and is also capable of degrading other proteins in the...

  • Plasmin.  // Encyclopedic Reference of Molecular Pharmacology;2004, p747 

    An encyclopedia entry for plasmins is presented. It refers to the serine protease that is responsible for degradation of fibrin during activation of the fibrinolytic system. Plasmin cleaves fibrin into soluble fibrin degradation products.

  • MODELING, ADME SCREENING & QSAR STUDIES ON FACTOR-XA INHIBITORS. NARAYANAN, SIBI; VELMURUGAN, D. // International Journal of Pharma & Bio Sciences;Apr2014, Vol. 5 Issue 2, pP-19 

    Thromboembolic disease is caused by improper functioning of the blood coagulation process. The serine protease Factor Xa plays a central role in the coagulation cascade. FXa inhibitors have been identified to maintain a patient's blood level within the therapeutic range and also shown to...

  • Safety evaluation of a recombinant plasmin derivative lacking kringles 2-5 and rt-PA in a rat model of transient ischemic stroke. Crumrine, R. Christian; Marder, Victor J.; McLeod Taylor, G.; LaManna, Joseph C.; Tsipis, Constantinos P.; Novokhatny, Valery; Scuderi, Philip; Petteway Jr., Stephen R.; Arora, Vikram // Experimental & Translational Stroke Medicine;2012, Vol. 4 Issue 1, p10 

    Background: Tissue type plasminogen activator is the only approved thrombolytic agent for the treatment of ischemic stroke. However, it carries the disadvantage of a 10-fold increase in symptomatic and asymptomatic intracranial hemorrhage. A safer thrombolytic agent may improve patient prognosis...

  • Design and Synthesis of para-Fluorophenylalanine Amide Derivatives as Thrombin Receptor Antagonists. Fujita, Tsugumi; Nose, Takeru; Nakajima, Masahide; Inoue, Yoshihisa; Costa, Tommaso; Shimohigashi, Yasuyuki // Journal of Biochemistry;1999, Vol. 126 Issue 1, p174 

    An antagonist specific for the thrombin receptor is expected to be a remedy for thrombosis. Structure-activity studies of thrombin receptor-tethered ligand SFLLRNP have revealed the importance of the Phe-2-phenyl group in receptor recognition and the replacement of the Phe-2 by...

  • Plasmin System.  // Encyclopedic Reference of Cancer;2001, p700 

    A definition of the term "plasmin system" is presented. It refers to a system that is composed of the cell membrane-bound serine protease urokinase-type plasminogen activator (u-PA), which targets plasminogen, an inactive serine protease precursor. It is produced by the liver cells and is found...

  • INTRAVENOUS ADMINISTRATION OF FIBRINOLYSIN: ITS SYSTEMIC TOXICITY AND EFFECT UPON COMPONENTS OF THE COAGULATION MECHANISM. Moser, Kenneth M. // Angiology;Aug1959 Part 2, Vol. 10 Issue 4, p253 

    1. In the doses used, the toxic potential of fibrinolysin is limited primarily to temperature elevation. In the absence of prophylactic medication, a febrile reaction occurred in 44.4 per cent of the patients, and could be correlated only with the presence of extensive thrombotic material. 2....

  • THE USE OF FIBRINOLYSIN IN THE PREVENTION OF THROMBUS FORMATION IN SMALL ARTERY ANASTOMOSES. Engler, Harold S.; Christopher, Phillip; Moretz, William H. // Angiology;Aug1959 Part 2, Vol. 10 Issue 4, p259 

    A study of the use of fibrinolysin in the prevention of thrombus formation in small artery anastomoses is reported. Under the conditions of this experiment no beneficial effect was observed. Our experience with the use of fibrinolysin in 9 vascular operations is also described briefly. With the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics